ArticleBlood advances2019
Heterogeneity in neutrophil responses to immune complexes.
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Manuka honey and its component, methyl syringate, shift neutrophil release profiles from pro-inflammatory while preserving pro-regenerative growth factor releaseFrontiers in immunology · 2026Article
- Utilizing High-Throughput Screening of dHL-60 Inflammatory Behaviors to Evaluate Honey-Derived Molecules' Potential as Immunomodulatory Biomaterial Additives.Journal of inflammation research · 2026Article
- Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2025Article
- Methyl Syringate: A Primary Driving Factor in Manuka Honeys Ability to Ameliorate Neutrophil Intracellular ROS Activity and NETosis.Frontiers in bioscience (Landmark edition) · 2024Article
- Non-infectious immune complexes downregulate the production of interferons and tumor necrosis factor-α in primary porcine alveolar macrophagesFrontiers in veterinary science · 2024Article
- Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets.International journal of molecular sciences · 2023Review
- Neutrophil functional heterogeneity is a fixed phenotype and is associated with distinct gene expression profiles.Journal of leukocyte biology · 2022Article
- Minimal role for the alternative pathway in complement activation by HIT immune complexes.Journal of thrombosis and haemostasis : JTH · 2022Article
- Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.Blood · 2021Article
- Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.Frontiers in pharmacology · 2021Review
- Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Pathogenesis of heparin-induced thrombocytopenia.Translational research : the journal of laboratory and clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Immune complexes (ICs) can trigger inflammation and thrombosis, in part, by activating neutrophils. Much attention has focused on the serologic characteristics of ICs and Fc receptors associated with cellular activation, but few studies have examined host susceptibility to neutrophil activation by ICs. Here, we use a novel whole blood system to investigate the ability of ICs to cause neutrophil activation and degranulation. Using monoclonal anti-platelet factor 4/heparin (PF4/heparin), anti-protamine/heparin antibodies, patient-derived anti-PF4/heparin antibodies, and heat-aggregated immunoglobulin G as model ICs, we demonstrate that heparin-containing ICs cause robust, heparin-dependent neutrophil activation and degranulation which is mediated by both FcγRIIa and complement. Longitudinal testing over a 1-year period shows that an individual's neutrophil response to ICs represents a fixed phenotype resulting in high, intermediate, or low reactivity. Examination of individuals at the extremes of reactivity (high vs low) shows that phenotypic variation resides in the cellular compartment and is correlated with host white blood cell count and absolute neutrophil count, but not age, sex, race, polymorphisms in neutrophil Fcγ receptors, or CR1, CR3, and Fcγ receptor expression on neutrophils. Together, these studies demonstrate that susceptibility to neutrophil activation by ICs is intrinsic to the host and is likely genetic in origin. These findings may be relevant to the heterogeneous clinical outcomes seen in patients with heparin-induced thrombocytopenia and other IC-mediated disorders and could potentially identify patients at high risk for thrombotic and inflammatory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.